Active ingredients: Levodopa 100 mg + Benserazide 25 mg per tablet
Dosage form: Dispersible, scored tablets for oral suspension
Pack size: 60 tablets
Manufacturer: Roche (France/Germany)
Route: Oral use
Modopar by Roche is a combination of levodopa, a dopamine precursor that crosses the blood-brain barrier, and benserazide, a peripheral decarboxylase inhibitor that prevents levodopa breakdown outside the brain and dramatically increases its central effect while reducing peripheral side effects.
Levodopa therapy has been the gold standard of Parkinson's disease management for over five decades. Dispersible tablets dissolve in water or can be chewed, which is convenient for patients with swallowing difficulties and allows flexible dosing.
The dose is highly individual and determined by the neurologist. Treatment usually starts with one tablet (100/25 mg) 1-3 times daily and is titrated gradually. Dispersible tablets may be dissolved in a small amount of water or taken whole with liquid. Take 30 minutes before or 1 hour after meals for better absorption.
Dose adjustments are made only by the treating physician; abrupt discontinuation should be avoided.
Modopar and Madopar are the same Roche combination (levodopa + benserazide); Modopar is the brand name used in certain countries. Both contain identical active substances.
Benserazide prevents levodopa breakdown in the body outside the brain, so more levodopa reaches the brain and peripheral side effects are reduced.
Yes, Modopar 125 is dispersible: the tablet can be dissolved in a small amount of water or chewed.
Yes, it is a prescription-only medicine managed by a neurologist.
Combinations (dopamine agonists, MAO-B inhibitors, COMT inhibitors) are common but must be managed by the physician.
Ask a question or inquire about delivery to your country


